Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.5.1.3 (
dihydrofolate reductase
)
5,819
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The mechanisms of adaptation to inactivation of essential genes remain unknown. Here we inactivate
E. coli
dihydrofolate reductase
(
DHFR
) by introducing D27G,N,F chromosomal mutations in a key catalytic residue with subsequent adaptation by an automated serial transfer protocol. The partial reversal G27- > C occurred in three evolutionary trajectories. Conversely, in one trajectory for D27G and in all trajectories for D27F,N strains adapted to grow at very low metabolic supplement (folAmix) concentrations but did not escape entirely from supplement auxotrophy. Major global shifts in metabolome and proteome occurred upon
DHFR
inactivation, which were partially reversed in adapted strains. Loss-of-function mutations in two genes,
thyA
and
deoB
, ensured adaptation to low folAmix by rerouting the
2-Deoxy-D-ribose
-phosphate metabolism from glycolysis towards synthesis of dTMP. Multiple evolutionary pathways of adaptation converged to a suboptimal solution due to the high accessibility to loss-of-function mutations that block the path to the highest, yet least accessible, fitness peak.
...
PMID:Adaptation to mutational inactivation of an essential gene converges to an accessible suboptimal fitness peak. 3157 12